Then indoximod entered phase II, it has been studied in several types of cancer (see Table 1 for detailed results) showed that the combination of indoximod with other therapies including cancer vaccines (Sipuleucel-T/Adenovirus-p53 transduced dendritic cell (DC) Vaccine), checkpoint inhibitors (pembrolizumab/nivolumab/Ipilimumab) and chemotherapy showed markedly enhanced the antitumor efficacy (Jha et al., 2017; Soliman et al., 2018). The gene discussed is TP53; the disease is cancer.